GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Net Margin %

AUPH (Aurinia Pharmaceuticals) Net Margin % : 2.39% (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Aurinia Pharmaceuticals's Net Income for the three months ended in Dec. 2024 was $1.4 Mil. Aurinia Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $59.9 Mil. Therefore, Aurinia Pharmaceuticals's net margin for the quarter that ended in Dec. 2024 was 2.39%.

The historical rank and industry rank for Aurinia Pharmaceuticals's Net Margin % or its related term are showing as below:

AUPH' s Net Margin % Range Over the Past 10 Years
Min: -27794.03   Med: -4157.34   Max: 2.45
Current: 2.45


AUPH's Net Margin % is ranked better than
76.29% of 1004 companies
in the Biotechnology industry
Industry Median: -135.865 vs AUPH: 2.45

Aurinia Pharmaceuticals Net Margin % Historical Data

The historical data trend for Aurinia Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Net Margin % Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -204.88 -396.81 -80.71 -44.45 2.45

Aurinia Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.60 -21.37 1.26 21.17 2.39

Competitive Comparison of Aurinia Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Net Margin % falls into.



Aurinia Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aurinia Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=5.752/235.133
=2.45 %

Aurinia Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=1.429/59.867
=2.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurinia Pharmaceuticals  (NAS:AUPH) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Aurinia Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals Business Description

Traded in Other Exchanges
Address
14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott Michael Habig officer: Chief Commercial Officer #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
R. Hector Mackay-dunn director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w. director #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Daniel Billen director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Jill Leversage director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Matthew Maxwell Donley officer: Ex VP, Intern'l Operations 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Stephen P. Robertson officer: EVP, General Counsel #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Joseph M Miller officer: Chief Financial Officer C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Peter Greenleaf director, officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Volker Knappertz officer: EVP, Research and Development SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster director C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037